To the Market | GenomeWeb

To the Market

The European Commission has given its seal of approval to the continent’s first gene therapy — a treatment for a lipid-processing disorder — which will be sold in Europe beginning in late 2013, The Scientist reports.

According to the article, the EC has approved the use of Glybera, a therapy that “utilizes viral vectors to deliver DNA encoding a lipid-processing enzyme to patients lacking a functional copy due to a gene mutation.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.